ALL DISPATCHES

THE DAILY DISPATCH · NOVEMBER 7, 2026

New trial and cure signals keep compounding

The pace of translation remains intense: there are 21,453 active gene, cell, mRNA, and SI trials worldwide, with 37 new Wire signals and 9 new Cure research entries in the last 24 hours. Today’s research highlights range from therapeutic direction-setting for chronic hepatitis B in the United States to immunologically oriented nanotherapy work aiming to preserve graft tolerance during infection. On the enabling-tech side, RPFace introduces a fairness-focused benchmark for protein–RNA interface prediction, while stem.MAP combines proteomics and machine learning to identify cell-type-specific protein complexes. Across cure and capability, the signal is consistent: the ecosystem is not slowing, and targeted efforts—from immune tolerance to better molecular prediction—are converging. The window is still open.

THE SIGNAL

ClinicalTrials.gov census lists 21,453 active gene, cell, mRNA and SI trials worldwide.

THE STAKES

More active trials mean faster learning cycles for therapies that could convert today’s unmet needs—like chronic hepatitis B—into broadly testable cures.

THE WINDOW

Watch for how today’s hepatitis B direction work, tolerogenic nanotherapy under infection, and new protein–RNA interface benchmarks translate into near-term study readouts before momentum diffuses.

21,453Active trials worldwide (census)
Preserved copy

An independent copy of this edition is kept by the Internet Archive: https://web.archive.org/web/20261109110907/https://negativeresistance.com/dispatch/2026-11-07

Permalink: https://negativeresistance.com/dispatch/2026-11-07 · How this site is preserved